Introduction
============

Influenza is more likely to cause severe illness and has increased risk for hospitalization or death in pregnant women than in non-pregnant women.[@b1]--[@b4] This predisposition can be explained by changes in the immune system and the pulmonary and cardiovascular physiology of pregnant women.[@b5] In addition, children of unvaccinated women seem to be more likely to have influenza.[@b6] Thus, if published and ongoing studies can show that vaccination against seasonal influenza during pregnancy is safe, immunogenic, and clinically beneficial for the mother and her newborn, it would be a highly advisable measure for prevention and control because it would target two high-risk groups with one vaccine dose.[@b4],[@b7] As current knowledge tends to support such a view, the Strategic Advisory Group of Experts in Immunization (SAGE) of the World Health Organization (WHO) recently specified that pregnant women are the highest priority group for influenza vaccination. The SAGE also noted that where countries are considering initiating or expanding influenza vaccination programs, pregnant women should be the highest priority group.[@b8]--[@b10] In the United States, the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) similarly recommends now that during the influenza season, all women who are or will be pregnant should be vaccinated against influenza.[@b11]

The Global Influenza Initiative (GII) has been attentive to these new recommendations. However, evidence regarding influenza vaccination and pregnancy is, overall, of low quality, which makes continuous reviewing a must to support recommendations.[@b12] The GII, founded in 2012, is an international expert scientific group composed of scientists, researchers, and clinicians with expertise in epidemiology, infectious diseases, immunology, and public health. The aim of the GII is to strengthen and communicate scientific evidence on the epidemiology and burden of disease of influenza, raise the profile of influenza as an important vaccine-preventable disease, and outline the strategies for disease prevention, intervention, and management. The GII is funded by Sanofi Pasteur, but the recommendations are made by the group members independently of the funding source. The main objective of the present document was to review and analyze current evidence surrounding the burden of influenza in pregnant women and their newborns, as well as the evidence on safety, immunogenicity, and clinical benefits of vaccination, to develop the GII recommendations regarding seasonal vaccination of pregnant women.

Influenza burden during pregnancy
=================================

There is a heavy disease burden due to seasonal and pandemic H1N1 influenza in pregnant women and their newborns, although the evidence comes mainly from retrospective cohorts and from the 2009 pandemic.[@b2],[@b3],[@b13]--[@b18],[@b20] Pregnant women are at an increased risk for influenza-related complications due to changes in their cardiac, respiratory, and immune systems.[@b1],[@b5],[@b19],[@b21],[@b23] During the 2009 H1N1 pandemic, pregnant women were at higher risk for severe disease, leading to the need for hospitalization or admission to an intensive care unit, as compared to non-pregnant women and the general population.[@b22] Five percent of all deaths from pandemic influenza occurred in pregnant women in the United States, although they represented only ∼1% of the population;[@b18],[@b23] a systematic review found that influenza hospitalization increased in pregnancy but not influenza mortality.[@b20] Studies suggest that maternal risk is the greatest during the third trimester, as compared to women at early pregnancy stages.[@b5],[@b18] Regarding the infant, maternal disease increases the risk for premature labor and delivery, fetal loss, small-for-gestational-age infants, and low birth weight.[@b15],[@b24],[@b25] Children born to women with pH1N1 illness during pregnancy were at increased risk for low birth weight (OR, 1·8), premature birth (OR, 2·2), and death (OR, 4·5).[@b15]

Safety of influenza vaccination in pregnancy
============================================

Safety is the most important factor to make an unambiguous recommendation to vaccinate all women who are or will be pregnant during the influenza season. During the past few decades, the inactivated influenza vaccine (IIV) has been administered to millions of pregnant women with no serious adverse events for the mother, fetus, or newborn.[@b7],[@b26]--[@b32] This safety profile remains positive throughout the three trimesters of pregnancy.[@b30] The US-based Vaccine Adverse Event Reporting System has shown no safety concerns over the past 20 years in the vaccination of pregnant women.[@b33] The Global Advisory Committee on Vaccine Safety reviewed in 2012 the safety data available for influenza vaccines derived from clinical trials, observational studies, and spontaneous reporting, concluding that 'the data confirm the safety of non-adjuvanted trivalent inactivated seasonal influenza vaccines in pregnancy'.[@b34] A recent randomized trial with IIV in 2310 pregnant women showed that injection-site reactions were more frequent in vaccinated than in placebo recipients (no other significant differences in solicited reactions were found).[@b35] Neither the seasonal nor the pandemic IIV has been associated with teratogenicity when administered during the first trimester,[@b36] although there is still concern because few studies have assessed safety at that stage of pregnancy, and the current ongoing clinical trials also do not do so. Therefore, influenza vaccine safety in the first trimester is an issue requiring more evidence before anybody can ensure that there are no such risks at this pregnancy stage. Moreover, no studies have compared safety and clinical benefit across IIV reformulated from year to year. Importantly, however, no study has ever found an increased risk of either maternal complications or untoward fetal outcomes associated with IIV.[@b37] In addition, no scientific evidence exists that vaccines that still include thimerosal, a mercury-containing compound, increase the number of adverse effects among children born to women who received influenza vaccine during pregnancy.[@b38]

Immunogenicity of the influenza vaccine during pregnancy
========================================================

Immunization against influenza induces protective antibodies for both mothers and their infants; this is critical as no vaccine is licensed for infants aged \<6 months. After vaccination, pregnant women have protective concentrations of anti-influenza antibodies, reaching levels similar to those previously reported in non-pregnant adults.[@b32],[@b39] Vaccination confers antibodies to newborns,[@b32],[@b40]--[@b43] and the passive transfer of the persistent maternal antibodies to infants has been documented.[@b39],[@b40],[@b42]--[@b45] In a recent randomized trial in 376 mothers and their newborns, influenza vaccination during pregnancy was highly immunogenic for both.[@b35] Immunization \<15 days before delivery, however, does not increase hemagglutination inhibition antibody titers in newborns.[@b42]

Clinical benefit of the influenza vaccination during pregnancy
==============================================================

Clinical efficacy of the IIV and the size of its effect remain subjects of debate due to the scarcity of randomized trials; the interpretation of results of other trials can be complicated by the fact that observational studies are prone to biases. Most data from non-randomized trials suggest that vaccination during pregnancy confers clinical benefits in both the pregnant woman and her newborn.[@b6],[@b30],[@b46]--[@b49] For example, respiratory illness with fever has been shown to be reduced in pregnant women, while in infants, findings include a reduction in laboratory-confirmed influenza (LCI) and number of small-for-gestational-age babies, along with higher birth weights.[@b6],[@b47] A case-controlled study found that 42% of pregnant women with confirmed influenza had been vaccinated during the study season compared to 58% and 63% among influenza-negative controls and matched acute respiratory infection-negative controls, respectively, for a vaccine efficacy of 44--53%.[@b50] In a non-randomized prospective cohort study, maternal influenza vaccination during pregnancy was associated with a reduced risk for influenza infection \[relative risk (RR) 0·59\] and hospitalization for influenza-like illness (ILI) (RR 0·61) among infants aged \<6 months; increased antibody titers were also noted in infants at birth and up to 2--3 months of age.[@b51] Sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), there are four completed clinical trials assessing seasonal and A(H1N1) 2009 vaccines in pregnant women; the primary objective was to evaluate safety and immunogenicity (Table[1](#tbl1){ref-type="table"}). Immunogenicity appears to be strong, and in the studies comparing immunogenicity in pregnant versus non-pregnant women, the response is similar; it is not possible, however, to obtain systematized information from these studies due to their small sample size and non-uniform design, as reported already by Adegbola *et al*.[@b7] On the other hand, a retrospective study, using data from clinical records, found no reduction in ILI among vaccinated pregnant women or their children.[@b31] In another big retrospective cohort study in 41 129 infants, consultations for respiratory diseases among children of vaccinated mothers were not significantly reduced.[@b52]

###### 

Clinical trials of seasonal and A(H1N1) 2009 vaccines evaluating safety and immunogenicity in pregnant women

  Identifier, Clinicaltrials.gov   Year         Vaccine                                Comparisons                                                                                                                                       Pregnant women, *n*           Design, results
  -------------------------------- ------------ -------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------- -------------------------------------------------------------------------------------------------------------------
  NCT00905125                      2008--2009   Trivalent IIV, seasonal                Compared influenza virus vaccines Fluzone® (Sanofi Pasteur, Swiftwater, PA, USA) versus Fluarix® (GlaxoSmithKline, Dresden, Germany). 0·5 ml IM   102                           Randomized No safety problems detected. Immunogenicity at 28 days post-vaccination similar for both vaccines
  NCT01173211                      2010--2011   Trivalent IIV, seasonal                Compared influenza virus vaccines Fluzone®, Fluarix®, and Agriflu® (Novartis Vaccines and Diagnostics Inc., Cambridge, MA, USA). 0·5 ml IM        139 (44 non-pregnant women)   Randomized, pregnant women and non-pregnant controls No safety problems detected. Immunogenicity not reported yet
  NCT00963430                      2009         Unadjuvanted, inactive H1N1 pandemic   Compared two 25 μg versus two 49 μg of hemagglutinin doses (Sanofi Pasteur), administered 21 days apart                                           120                           Randomized, pregnant women No safety problems detected. Immunogenicity similar for both doses. Published[@b32]
  NCT00992719                      2009         Unadjuvanted, inactive H1N1 pandemic   Compared 15 versus 30 μg of hemagglutinin doses (Novartis Vaccines and Diagnostics Inc.) administered 21 days apart                               56 (28 non-pregnant women)    Randomized, pregnant women and non-pregnant controls No safety problems detected. Immunogenicity not reported yet

IIV, inactivated influenza vaccine.

To date, the evidence of highest quality on vaccine efficacy comes from two randomized controlled trials. In a small study with 340 mothers in Bangladesh, Zaman *et al*.[@b6] provided trivalent IIV vaccination during the third pregnancy trimester with a follow-up until 24 weeks after birth. There were fewer cases of LCI in children from vaccinated mothers than among infants in the control group, with a significant vaccine effectiveness of 63%; among the vaccinated mothers, there was a significant reduction of 36% in the rate of respiratory illness with fever. In the second trial, a large double-blind, placebo-controlled study in South Africa, Madhi *et al*. studied 2116 women who were not infected with HIV and 194 women who were infected with HIV.[@b35] They followed mothers and their children until 24 weeks after birth, finding a significant drop of reverse transcriptase polymerase chain reaction (RT-PCR)-confirmed influenza from 3·6% to 1·8% for mothers and from 3·6% to 1·9% for their children, for a significant vaccine-efficacy rate of 50·4% and 48·8%, respectively \[number needed to treat (NNT), 56 and 59, respectively\]. The drop for the HIV-infected cohort was from 17% to 7% for vaccinated mothers, with a significant vaccine efficacy of 57·7% (NNT, 10) and from 6·8% to 5% for their children, for a non-significant vaccination efficacy of 26·7%.[@b35] Unlike the study in Bangladesh, this South Africa study did not show reduction in the overall outcomes of clinical respiratory illness in either mothers or infants.

Ongoing clinical trials in pregnant women
=========================================

As already discussed, there are scarce data from randomized clinical trials of IIVs in pregnancy. It is therefore encouraging that, in addition to the South Africa study,[@b35] two more late-phase clinical trials sponsored by the Bill and Melinda Gates Foundation are under way.

*NCT01034254* This phase 3 study in Nepal has an estimated enrollment of 3000 pregnant women. Primary outcomes in pregnant women and their infants aged ≤6 months include incidence of ILI or LCI episodes; distribution of causes of febrile illness and the incidence of clinic visits and hospitalizations; incidence of low birth weight; the distribution of birth weight; and gestational age and growth of the infants.

*NCT01430689* The number of enrolled women in this phase 4 study in Mali is not yet reported; the study compares pregnant women randomized to receive IIV or meningococcal conjugate vaccine during the third trimester of pregnancy. Primary outcomes are the number of infants with influenza (across 2 years) and incidence of LCI in infants aged ≤6 months.

It is anticipated that when the results of these trials become available, more gaps in the knowledge of influenza vaccination during pregnancy will be closed.

Cost-effectiveness and timing of the influenza vaccination during pregnancy
===========================================================================

There is limited health economics evidence on influenza vaccination in pregnant women, but vaccination with either the seasonal or pandemic vaccine has been shown to be cost-effective,[@b53] with most benefit arising from prevention of symptomatic episodes.[@b54] During pandemic and seasonal influenza seasons, vaccination of pregnant women becomes most cost-effective when the prevalence and severity of influenza increase.[@b55],[@b56] The timing of influenza vaccination of pregnant women within the influenza season is important for cost-effectiveness -- the greatest benefit to infants occurred when their pregnant mothers were vaccinated within the first 4 weeks of vaccine availability.[@b54],[@b57] Furthermore, when all women who were pregnant at the time of vaccine availability were vaccinated, vaccination of newly pregnant women seemed to provide benefits for mothers but not for infants.[@b57] Unfortunately, although the first priority is to protect the mother, if vaccination is not given in the third trimester of pregnancy, the newborn is unlikely to derive much benefit. In this regard, there is some evidence from the TDaP vaccine suggesting that newborns benefit more if the vaccine is given in the third trimester.[@b59] Thus, factors influencing cost-effectiveness include attack and death rate, at what stage of pregnancy vaccination occurs, potential vaccine protection for infants, potential persistence of vaccine protection, when during the influenza season vaccination occurs; cost of vaccine delivery; and vaccine efficacy.

Challenges to implementing timely vaccination strategies
========================================================

Inactivated influenza vaccines are licensed for use in women before, during, and after pregnancy. Thus, vaccination of pregnant women, and of women who expect to become pregnant during the influenza season, is universally recommended across all trimesters by the WHO, the CDC, and the Canadian Guideline Committee.[@b8]--[@b10],[@b58] To achieve this goal, healthcare providers' recommendations are key to vaccine uptake.

In the Northern and Southern Hemispheres, data suggest that the greatest clinical benefit for infants occurs if the IIV is administered within the first weeks of availability of the vaccine, at the beginning of the influenza season,[@b54],[@b57] regardless of the pregnancy trimester. This strategy confers maximum protection in the mother and fetus (administering vaccine long before the start of the season is unlikely to have any benefit). It is unclear when it is optimal to vaccinate pregnant women who live in tropical regions, where influenza tends to occur year-round; ongoing clinical trials are not assessing this. Because inactivated trivalent influenza vaccine (TIV) contains only one B strain, there is a new inactivated quadrivalent influenza vaccine containing both circulating B lineages, which has been used in healthy adults, resulting in superior immunogenicity for the added B strain, without affecting the antibody response to the TIV strains, and without compromising safety.[@b60]

There is still a lot we do not know about the timing of influenza vaccinations in pregnancy, including (i) the optimal vaccination strategies for pregnant women with comorbidities; (ii) the impact that breastfeeding has on protection duration, the effect that breastfeeding has on vaccination strategies; and (iii) the vaccination strategies for developing countries.[@b4]

GII recommendations for influenza vaccination during pregnancy
==============================================================

Based on our review, the GII recommends the vaccination of women during pregnancy because evidence of high and moderate quality suggests that internationally available IIVs reduce the risk of ILI in mothers and infants as well as the risk of LCI in infants. In addition, the GII recommendation considers that the IIVs lack teratogenicity, induce an immunogenic response of the mothers and newborns, and are contraindicated in children younger than 6 months. Postpartum women can receive either the IIV or the live attenuated influenza vaccine. In addition, the GII proposes several other recommendations regarding vaccination during pregnancy (Table[2](#tbl2){ref-type="table"}). We require future research on specific knowledge gaps on vaccine efficacy and its duration, and we expect the studies in progress to yield new data, which we will incorporate in future recommendations.

###### 

Global Influenza Initiative (GII) recommendations regarding influenza vaccination during pregnancy

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1\. To prevent seasonal influenza morbidity and mortality in infants and their mothers, all pregnant women, regardless of trimester, should be vaccinated with the inactivated influenza vaccine (IIV)
  2\. Pregnant women should not receive the live attenuated influenza vaccine (LAIV)
  3\. Postpartum women, even if they are breastfeeding, can receive either the IIV or LAIV
  4\. Because it is difficult to predict the onset of the influenza season, routine influenza vaccination is recommended for pregnant women and those who expect to be pregnant during the influenza season. The duration of each geographic region's influenza season should be an important consideration because in some countries, influenza is seasonal, whereas in others it occurs year-round. In regions with defined influenza seasons, the GII recommends the vaccination of pregnant woman as a priority group immediately after the vaccine becomes available, regardless of the pregnancy trimester
  5\. For countries where vaccination of influenza is starting or expanding, the GII recommends that pregnant women have a high priority
  6\. For countries with programs of immunization against influenza, where pregnant women are not considered as a priority for vaccination, a policy change is required to consider them as such
  7\. Vaccination coverage of pregnant women is low worldwide; therefore, there is a need to encourage education of all healthcare providers (not solely obstetricians) that a pregnant woman is likely to see that maternal immunization is effective, well tolerated, and safe. If the healthcare professional does not recommend the vaccine, even highly educated women are unlikely to receive it
  8\. Wherever possible, influenza vaccination during pregnancy must be administered at least 15 days before delivery
  9\. Where quadrivalent IIV is available, it can be administered in pregnant women instead of the trivalent one
  10\. Influenza vaccination should become standard in women's health care
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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